Amyloidosis: A clinico-pathophysiological synopsis

Seminars in Cell and Developmental Biology

Volumn 15, Issue 1, 2004, Pages 39-44

  Hirschfield, Gideon M ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b LUTON AND DUNSTABLE HOSPITAL   (United Kingdom)

Author keywords

Amyloidosis; Glycosaminoglycans; Serum amyloid P component; Therapeutics

Indexed keywords

1,3 PROPANEDISULFONIC ACID; AMYLOID; AMYLOID A PROTEIN; AMYLOID P COMPONENT; ANTIBODY; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; BETA 2 MICROGLOBULIN; CYSTATIN C; FIBRINOGEN; FLUFENAMIC ACID; GELSOLIN; GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN MIMETIC AGENT; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; NONSTEROID ANTIINFLAMMATORY AGENT; PARAPROTEIN; PENTRAXIN; PEPTIDE; PREALBUMIN; PROTEIN ANTIBODY; PROTEIN INHIBITOR; PROTEIN PRECURSOR; PROTEIN SUBUNIT; SERUM AMYLOID P; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ALZHEIMER DISEASE; AMYLOIDOSIS; BETA 2 MICROGLOBULIN AMYLOIDOSIS; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CLASSIFICATION; EXTRACELLULAR SPACE; FIBER; GENETIC ANALYSIS; GENETIC DISORDER; GLOMERULUS; HEMODIALYSIS; HOST; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN VIVO STUDY; KIDNEY TUBULE; LIVER TRANSPLANTATION; MONOCLONAL IMMUNOGLOBULINEMIA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; SENILE AMYLOIDOSIS; SOLUBILITY; TISSUE STRUCTURE; VACCINATION;

EID: 0842281548     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2003.12.013     Document Type: Conference Paper

References (32)

1. Pepys MB, Hawkins PN. Amyloidosis. In: Warrell DA, et al., editors, Oxford textbook of medicine. Oxford: Oxford University Press; 2003. p. 162-73.
2. Merlini G., Bellotti V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349:2003;583-596.
3. Gillmore J.D., Hawkins P.N., Pepys M.B. Amyloidosis: a review of recent diagnostic and therapeutic developments. Brit. J. Haematol. 99:1997;245-256.
4. Pepys M.B. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356:2001;203-211.
5. Lachmann H.J.et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N. Engl. J. Med. 346:2002;1786-1791.
6. Drenth J.P., van der Meer J.W. Hereditary periodic fever. N. Engl. J. Med. 345:2001;1748-1757.
7. Aganna E.et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis. Rheum. 46:2002;2445-2452.
8. Hawkins P.N., Lachmann H.J., McDermott M.F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348:2003;2583-2584.
9. Dobson CM. Protein folding and its links with human disease. Biochem Soc Symp 2001:1-26.
10. Bucciantini M.et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416:2002;507-511.
11. Kisilevsky R., Fraser P. Proteoglycans and amyloid fibrillogenesis. Ciba Found. Symp. 199:1996;58-67.
12. Pepys MB. The Lumleian lecture. C-reactive protein and amyloidosis: from proteins to drugs? In: Williams G, editor. Horizons in medicine. London: Royal College of Physicians of London; 1999. p. 397-414.
13. Hawkins P.N. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr. Opin. Nephrol. Hypertens. 11:2002;649-655.
14. Murphy C.L.et al. Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am. J. Clin. Pathol. 116:2001;135-142.
15. Gillmore J.D.et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 358:2001;24-29.
16. Lachmann H.J.et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br. J. Haematol. 122:2003;78-84.
17. Dominguez D.I., De Strooper B. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. Trends Pharmacol. Sci. 23:2002;324-330.
18. Sacchettini J.C., Kelly J.W. Therapeutic strategies for human amyloid diseases. Nat. Rev. Drug Discov. 1:2002;267-275.
19. Hammarstrom P.et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 299:2003;713-716.
20. Sigurdsson E.M.et al. In vivo reversal of amyloid-beta lesions in rat brain. J. Neuropathol. Exp. Neurol. 59:2000;11-17.
21. Dumoulin M.et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature. 424:2003;783-788.
22. Kisilevsky R., Szarek W.A. Novel glycosaminoglycan precursors as anti-amyloid agents part II. J. Mol. Neurosci. 19:2002;45-50.
23. O'Nuallain B., Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. USA. 99:2002;1485-1490.
24. Hrncic R.et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am. J. Pathol. 157:2000;1239-1246.
25. Hock C.et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 8:2002;1270-1275.
26. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3:2002;824-828.
27. Hock C.et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 38:2003;547-554.
28. Botto M.et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat. Med. 3:1997;855-859.
29. Pepys M.B.et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 417:2002;254-259.
30. Esposito G.et al. Structural and folding dynamic properties of the T70N variant of human lysozyme. J. Biol. Chem. 278:2003;25910-25918.
31. Abraham R.S.et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis AL. Blood. 101:2003;3801-3808.
32. Chiti F. Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc. Natl. Acad. Sci. U.S.A. 99(Suppl. 4):2002;16419-16426.